Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications.

Lauterbach EC, Shillcutt SD, Victoroff J, Coburn KL, Mendez MF.

J Neuropsychiatry Clin Neurosci. 2010 Spring;22(2):130-54. doi: 10.1176/appi.neuropsych.22.2.130. Review.

PMID:
20463108
2.

Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.

Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF.

J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):8-18. doi: 10.1176/appi.neuropsych.22.1.8. Review.

PMID:
20160205
3.

Psychopharmacological neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research.

Lauterbach EC, Mendez MF.

J Neuropsychiatry Clin Neurosci. 2011 Summer;23(3):242-60. doi: 10.1176/appi.neuropsych.23.3.242. Review.

PMID:
21948886
4.

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.

Forlenza OV, De-Paula VJ, Diniz BS.

ACS Chem Neurosci. 2014 Jun 18;5(6):443-50. doi: 10.1021/cn5000309. Epub 2014 May 6. Review.

5.

Neuroprotection in progressive brain disorders.

Djaldetti R, Lev N, Melamed E.

Isr Med Assoc J. 2003 Aug;5(8):576-80. Review.

6.

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.

Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P.

Expert Opin Investig Drugs. 2012 Sep;21(9):1267-308. doi: 10.1517/13543784.2012.703178. Epub 2012 Jun 28. Review.

PMID:
22741814
7.

Morphinan neuroprotection: new insight into the therapy of neurodegeneration.

Zhang W, Hong JS, Kim HC, Zhang W, Block ML.

Crit Rev Neurobiol. 2004;16(4):271-302. Review.

PMID:
15862109
8.

The antiapoptotic activity of melatonin in neurodegenerative diseases.

Wang X.

CNS Neurosci Ther. 2009 Winter;15(4):345-57. doi: 10.1111/j.1755-5949.2009.00105.x. Epub 2009 Oct 10. Review.

9.

Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.

Naoi M, Maruyama W.

Curr Pharm Des. 2010;16(25):2799-817. Review.

PMID:
20698822
10.

Duality of Antidepressants and Neuroprotectants.

Tizabi Y.

Neurotox Res. 2016 Jul;30(1):1-13. doi: 10.1007/s12640-015-9577-1. Epub 2015 Nov 27. Review.

11.

Neuroprotective agents in schizophrenia and affective disorders.

Krebs M, Leopold K, Hinzpeter A, Schaefer M.

Expert Opin Pharmacother. 2006 May;7(7):837-48. Review.

PMID:
16634707
12.

Natural polyphenols against neurodegenerative disorders: potentials and pitfalls.

Ebrahimi A, Schluesener H.

Ageing Res Rev. 2012 Apr;11(2):329-45. doi: 10.1016/j.arr.2012.01.006. Epub 2012 Feb 9. Review.

PMID:
22336470
13.

Progesterone and progestins: neuroprotection and myelin repair.

Schumacher M, Sitruk-Ware R, De Nicola AF.

Curr Opin Pharmacol. 2008 Dec;8(6):740-6. doi: 10.1016/j.coph.2008.10.002. Epub 2008 Nov 6. Review. Erratum in: Curr Opin Pharmacol. 2009 Apr;9(2):227.

PMID:
18929681
14.

Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.

Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA.

Exp Neurol. 2011 Jul;230(1):27-34. doi: 10.1016/j.expneurol.2010.04.006. Epub 2010 Apr 18. Review.

PMID:
20406638
15.

[Is good old minocycline a new neuroprotective drug?].

Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, Hernández-Guijo JM, Aguirre N, Galindo MF, Jordán J.

Rev Neurol. 2008 Jul 1-15;47(1):31-8. Review. Spanish.

16.

Sigma receptors as potential therapeutic targets for neuroprotection.

Nguyen L, Kaushal N, Robson MJ, Matsumoto RR.

Eur J Pharmacol. 2014 Nov 15;743:42-7. doi: 10.1016/j.ejphar.2014.09.022. Epub 2014 Sep 27. Review.

18.

Role of sigma-1 receptors in neurodegenerative diseases.

Nguyen L, Lucke-Wold BP, Mookerjee SA, Cavendish JZ, Robson MJ, Scandinaro AL, Matsumoto RR.

J Pharmacol Sci. 2015 Jan;127(1):17-29. doi: 10.1016/j.jphs.2014.12.005. Epub 2014 Dec 11. Review.

19.

Caspases and neuroprotection.

Bilsland J, Harper S.

Curr Opin Investig Drugs. 2002 Dec;3(12):1745-52. Review.

PMID:
12528311
20.

Neuroprotection and neurodegenerative diseases: from biology to clinical practice.

Akwa Y, Allain H, Bentue-Ferrer D, Berr C, Bordet R, Geerts H, Nieoullon A, Onteniente B, Vercelletto M.

Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):226-39. Review.

PMID:
16327350

Supplemental Content

Support Center